Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution

BackgroundGenomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.ResultsWe perform whole exome sequencing on four clear cell renal cell carcinomas removed from both kidneys of a patient with a germline VHL mutation. We report that tumors arising in this context are clonally independent and harbour distinct secondary events exemplified by loss of chromosome 3p, despite an identical genetic background and tissue microenvironment. We propose that divergent mutational and copy number anomalies are contingent upon the nature of 3p loss of heterozygosity occurring early in tumorigenesis. However, despite distinct 3p events, genomic, proteomic and immunohistochemical analyses reveal evidence for convergence upon the PI3K-AKT-mTOR signaling pathway. Four germline tumors in this young patient, and in a second, older patient with VHL syndrome demonstrate minimal intra-tumor heterogeneity and mutational burden, and evaluable tumors appear to follow a linear evolutionary route, compared to tumors from patients with sporadic clear cell renal cell carcinoma.ConclusionsIn tumors developing from a germline VHL mutation, the evolutionary principles of contingency and convergence in tumor development are complementary. In this small set of patients with early stage VHL-associated tumors, there is reduced mutation burden and limited evidence of intra-tumor heterogeneity.

[1]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[2]  A. F. Bennett,et al.  Experimental tests of the roles of adaptation, chance, and history in evolution. , 1995, Science.

[3]  Adrian E. Raftery,et al.  mclust Version 4 for R : Normal Mixture Modeling for Model-Based Clustering , Classification , and Density Estimation , 2012 .

[4]  G. Mills,et al.  Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.

[5]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[6]  R. Piñeiro,et al.  Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis , 2013, PloS one.

[7]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[8]  Q. She,et al.  4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.

[9]  D. Bhattacharya,et al.  Faculty Opinions recommendation of Genomic analysis of a key innovation in an experimental Escherichia coli population. , 2012 .

[10]  J. Salk Clonal evolution in cancer , 2010 .

[11]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[12]  M. Greaves,et al.  Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. , 2011, Blood.

[13]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[14]  J. Larkin,et al.  Epigenetic regulation in RCC: opportunities for therapeutic intervention? , 2012, Nature Reviews Urology.

[15]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[16]  C. Sander,et al.  Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.

[17]  Aleksey A. Porollo,et al.  p62 is a key regulator of nutrient sensing in the mTORC1 pathway. , 2011, Molecular cell.

[18]  M. Greaves,et al.  Leukemia in twins: lessons in natural history. , 2003, Blood.

[19]  A. Børresen-Dale,et al.  Copynumber: Efficient algorithms for single- and multi-track copy number segmentation , 2012, BMC Genomics.

[20]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[21]  T. Maffucci,et al.  Class II phosphoinositide 3-kinase C2alpha: what we learned so far. , 2011, International journal of biochemistry and molecular biology.

[22]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[23]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Beatty Replaying life's tape , 2006 .

[25]  Z. Szallasi,et al.  Parallel evolution of tumour subclones mimics diversity between tumours , 2013, The Journal of pathology.

[26]  R. Lenski,et al.  Historical contingency and the evolution of a key innovation in an experimental population of Escherichia coli , 2008 .

[27]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[28]  C. Sander,et al.  SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. , 2013, Cancer cell.

[29]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[30]  C. Waddington Canalization of Development and the Inheritance of Acquired Characters , 1942, Nature.

[31]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[32]  Thomas S. Ray,et al.  Life's Solution: Inevitable Humans in a Lonely Universe , 2006, Artificial Life.

[33]  J. Urano,et al.  Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells , 2007, Proceedings of the National Academy of Sciences.

[34]  E. Boerwinkle,et al.  dbNSFP v2.0: A Database of Human Non‐synonymous SNVs and Their Functional Predictions and Annotations , 2013, Human mutation.

[35]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[36]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[37]  T. Maeda,et al.  Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin* , 2008, Journal of Biological Chemistry.

[38]  Michael J. Harms,et al.  Historical contingency and its biophysical basis in glucocorticoid receptor evolution , 2014, Nature.

[39]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[41]  R. Houlston,et al.  Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia , 2013, Proceedings of the National Academy of Sciences.

[42]  H. Brauch,et al.  Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma , 1988, Nature.

[43]  J. Haines,et al.  Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma , 1988, Nature.

[44]  Vasyl Pihur,et al.  RankAggreg, an R package for weighted rank aggregation , 2009, BMC Bioinformatics.

[45]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[46]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[47]  Huanming Yang,et al.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.

[48]  Simion I. Chiosea,et al.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. , 2013, Cancer discovery.

[49]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[50]  J. Hailman Wonderful Life: The Burgess Shale and the Nature of History, Stephen Jay Gould. W. W. Norton, New York (1989), 347, Price $19.95 (U.S.A.), $27.95 (Canada) , 1991 .

[51]  Andrew H. Beck,et al.  A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. , 2014, Cancer discovery.

[52]  M. Xing,et al.  Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity* , 2013, The Journal of Biological Chemistry.

[53]  E. Messing,et al.  Regulation of receptor for activated C kinase 1 protein by the von Hippel–Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness , 2011, Oncogene.

[54]  L. Whyte Internal factors in evolution. , 1965, The Eugenics review.

[55]  Margaret C. Linak,et al.  Sequence-specific error profile of Illumina sequencers , 2011, Nucleic acids research.

[56]  W. Marston Linehan,et al.  Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.

[57]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[58]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[59]  B. Krause,et al.  S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer , 2011, PloS one.

[60]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[61]  R. Arceci Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia , 2012 .

[62]  Terry L. Smith,et al.  Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.

[63]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[64]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.